WAWim Adriaensen

Wim Adriaensen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wim Adriaensen has a total of 255 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Spatial mapping of Ethiopian cutaneous leishmaniasis lesions reveals distinct tissue level immune programs

    by Nidhi S. Dey, Thao-Thy Pham, Shoumit Dey, Mekibib Kassa, Tigist Mekonnen, Helina Fikre, Pieter Monsieurs, Myrthe Pareyn, Johan van Griensven, Malgorzata Domagalska, et al.

    Introduction: Human cutaneous leishmaniasis (CL) is a prevalent but neglected tropical disease characterised by inflammatory lesions that are either restricted to the site of the infected sand fly bite or disseminate to mucosae or within the skin. Compared to well-studied pre-clinical models, the nature and diversity of the tissue response in humans remains to be fully appreciated. Methods: We conducted an exploratory study using spatial transcriptomics on paired lesional and non-lesional skin punch biopsies from five Ethiopian CL patients (two infected with L. aethiopica , one with L. tropica , and two with species unconfirmed). We used reference-free deconvolution, morphology-guided regional analyses, and immunohistochemistry-based validation to characterise the tissue responses. Results and Discussion: We identified spatially distinct immunopathological tissue responses including: i) epithelial hyperplasia with interferon-stimulated keratinocytes, ii) cytotoxicity with tertiary lymphoid structures, iii) granulomatous inflammation with proinflammatory response, iv) granulomatous inflammation with M2-polarised myeloid cell responses, and v) fibrotic remodelling with active collagen synthesis. Each patient in this case series exemplified one of these tissue responses, but immunopathological features were not mutually exclusive. This study extends our understanding of Ethiopian CL immunopathology and provides a molecular and cellular context that can be applied in larger clinical cohorts for testing hypotheses regarding the host and/or parasite determinants of CL disease diversity.


  • Open Access

    Multi-drug tolerance in Leishmania persister-like cells

    by Allison Aroni-Soto, Pieter Monsieurs, Odin Goovaerts, Kaoutar Choukri, Basudha Khanal, Wim Adriaensen, Jean-Claude Dujardin, Michael P. Barrett, Malgorzata A. Domagalska

    Leishmaniasis is caused by parasitic protozoa of the genus Leishmania and is found widely across the tropics and sub-tropics, afflicting hundreds of thousands of people. The disease is notoriously difficult to treat. Here, we present evidence of the existence of persister-like cells in cultured Leishmania populations, induced upon exposure to normally lethal doses of antimony, a still used anti-leishmanial. Persisters are a small fraction of non-proliferative cells with reduced metabolism that are adapted to withstand a variety of environmental assaults, including lethal doses of antimicrobials. We show that Leishmania persister-like cells survive lethal doses of antimonials by adopting a quiescence phenotype characterised by reduced proliferation, constrained metabolism, diminished mitochondrial membrane potential and downregulated transcription of core metabolic pathways. What is more, these cells demonstrate cross-tolerance to other anti-leishmanial drugs. Wild-type persister-like cells reverted to similar levels of drug susceptibility once the antimony-induced pressure was removed. Surprisingly, cells from strains with genetic changes causing resistance to antimony acquired a level of hyper-resistance after transient passage through the quiescent state, without further genetic change. Our results demonstrate the extreme versatility of this eukaryotic pathogen in adaptation to drug pressure and highlight the need for the development of new anti-leishmanials targeting non-proliferative forms.

  • Breaking the deadlock in antigen discovery for Leishmania vaccines

    by Wim Adriaensen, Nicky de Vrij, Thao-Thy Pham, Kris Laukens, Pieter Meysman, Paul M. Kaye


  • Top Cited Papers
    Open Access

    Immunopeptidomics of cutaneous leishmaniasis patients reveals the natural antigenic landscape

    by Nicky de Vrij, Elise Pepermans, Louise Laurijssen, Thao-Thy Pham, Lauren Thijs, Kurt Boonen, Kadrie Ramadan, Ilse Maes, Yetemwork Aleka, Mekibib Kassa, et al.

    Introduction: Cutaneous leishmaniasis (CL) is a skin disease caused by Leishmania infection, for which no licensed human vaccine exists. Protective immunity is largely T cell–mediated and depends on antigen presentation by MHC molecules, yet the naturally presented epitopes during human disease remain poorly defined. Methods: To address this gap, we performed mass spectrometry–based immunopeptidomics on lesional biopsies from 27 Ethiopian CL patients spanning the full clinical spectrum. Results: We newly identified 333 MHC-I and 247 MHC-II epitopes from 398 L. aethiopica proteins, including 19 peptides and 51 antigens recurrently presented across patients of which several were also epitope-rich. Some peptides were also detected during early infection in a L. aethiopica –infected THP-1 monocyte model, highlighting their relevance from disease onset. Notably, despite the broad predictive coverage of NetMHCpan and NetMHCIIpan, these tools missed 20–70% of the naturally presented epitopes while predicting millions of candidates, underscoring the limitations of prediction-only vaccine pipelines. Discussion: This first comprehensive map of the Leishmania immunopeptidome in human disease reveals conserved and prevalent antigens that can inform rational vaccine design and deepen our understanding of protective T cell responses in leishmaniasis.


  • Open Access

    Spatial mapping of Ethiopian cutaneous leishmaniasis lesions reveals distinct tissue level immune programs

    by Nidhi Sharma Dey, Thao-Thy Pham, Shoumit Dey, Mekibib Kassa, Tigist Mekonnen, Helina Fikre, Pieter Monsieurs, SPATIAL CL Consortium, Myrthe Pareyn, Johan van Griensven, et al.

    Ethiopian cutaneous leishmaniasis (CL) shows remarkably heterogeneous clinical presentations, but the underlying immunopathological mechanisms driving this heterogeneity in disease presentation remains poorly understood. To characterise the local immune response in Ethiopian CL, we performed spatial transcriptomics on paired lesional and non-lesional skin punch biopsies from five Ethiopian CL patients. We used reference-free deconvolution, morphology-guided regional analyses, and immunohistochemistry to identify five spatially distinct immunopathological responses that could co-exist within individual lesions: i) epithelial hyperplasia with interferon-stimulated keratinocytes, ii) cytotoxicity with tertiary lymphoid structures, iii) granulomatous inflammation with proinflammatory response iv) granulomatous inflammation with M2-polarised myeloid cell responses, and v) fibrotic remodelling with active collagen synthesis. Future longitudinal studies are needed to distinguish whether these patterns represent discrete pathotypes or stages of disease progression and to enable immune-based patient stratification and precision therapeutic interventions.

  • Top Cited Papers
    Open Access

    From dogma to data: charting a path forward for clinico-immunological research in Ethiopian cutaneous leishmaniasis

    by Thao-Thy Pham, Saskia van Henten, Mikias Woldetensay, Mezgebu Silamsaw Asres, Eleni Ayele, Paul M. Kaye, Malgorzata Anna Domagalska, Jean-Claude Dujardin, Johan van Griensven, Wim Adriaensen

    Background: Rooted in long-standing assumptions and adapted from classifications mainly used for Latin American cutaneous leishmaniasis (CL), the nationally recommended clinical categories in Ethiopia for CL remain limited to localized cutaneous leishmaniasis (LCL), mucocutaneous leishmaniasis (MCL), and diffuse cutaneous leishmaniasis (DCL). However, these categories are associated with immune mechanisms which have not been validated in the Ethiopian context and thus risk misrepresenting the true clinical and immunopathological diversity. In this opinion piece, we will therefore outline key knowledge gaps and challenges in current clinico-immunological research on Ethiopian CL. Main body: In Ethiopia, Leishmania aethiopica is often assumed as the causative agent of these ‘LCL’, ‘MCL’ and ‘DCL’ forms, yet significant gaps in knowledge urge caution. For example, adoption of this ‘LCL’, ‘MCL’ and ‘DCL’ terminology and the associated immune mechanisms has led to inconsistent results. Most immunological studies on Ethiopian CL have focused on peripheral blood, resulting in little information about immune processes in the lesion, the original site of infection. Adding to the complexity, other species (including L. major , L. donovani and L. tropica as well as L. aethiopica hybrids) also circulate, with reports of Leishmania RNA virus co-infection. To address these challenges, we propose a multidimensional approach that combines standardized clinical documentation with appropriate lesion and blood sampling for in-depth profiling of both immune responses and parasite diversity. Adopting this holistic approach will require inclusive (inter)national collaborations with a focus on promoting equitable biobank and data sharing which will strengthen local research capacities. Conclusions: By addressing the main challenges and knowledge gaps in current clinico-immunological research through a multidimensional approach, this opinion aims to provide the tools to achieve a better and unbiased understanding of the immunopathogenesis of Ethiopian CL, a severe yet under-investigated disease. Such progress is essential for improving CL management in Ethiopia and aligns with the World Health Organization priority on controlling CL. Graphical


  • Open Access

    Determinants of long-term SARS-CoV-2 immune responses in asymptomatic-to-moderate COVID-19 patients in sub-Saharan Africa

    by Víctor L. de Rioja, Odin Goovaerts, Marta Vidal, John Amuasi, Anthony Afum-Adjei Awuah, Christian Kahusu Mwan-Za-K’a, Placide Mbala-Kingebeni, Ritha Nyembu Kibambe, Matthieu Tshitamba, Chirac Kazadi, et al.

    Immune responses after SARS-CoV-2 infection remain poorly characterized in African populations, despite widespread viral transmission and proportionally lo


  • Open Access

    Immunopeptidomics of cutaneous leishmaniasis patients reveals the natural antigenic landscape

    by Nicky de Vrij, Elise Pepermans, Louise Laurijssen, Thao-Thy Pham, Lauren Thijs, Kurt Boonen, Kadrie Ramadan, Ilse Maes, Yetemwork Aleka, Mekibib Kassa, et al.

    Cutaneous leishmaniasis (CL) is a skin disease caused by Leishmania infection, for which no licensed human vaccine exists. Protective immunity is largely T cell-mediated and depends on antigen presentation by MHC molecules, yet the naturally presented epitopes during human disease remain poorly defined. To address this gap, we performed mass spectrometry-based immunopeptidomics on lesional biopsies from 27 Ethiopian CL patients spanning the full clinical spectrum. We newly identified 333 MHC-I and 247 MHC-II epitopes from 398 L. aethiopica proteins, including 19 peptides and 51 antigens recurrently presented across patients of which several were also epitope-rich. Some peptides were also detected during early infection in a L. aethiopica-infected THP-1 monocyte model, highlighting their relevance from disease onset. Notably, despite the broad predictive coverage of NetMHCpan and NetMHCIIpan, these tools missed 20-70% of the naturally presented epitopes while predicting millions of candidates, underscoring the limitations of prediction-only vaccine pipelines. This first comprehensive map of the Leishmania immunopeptidome in human disease reveals conserved and prevalent antigens that can inform rational vaccine design and deepen our understanding of protective T cell responses in leishmaniasis.

  • Open Access

    No Distinct Cytokine, Chemokine, and Growth Factor Blood Profile Associated With Monkeypox Virus Clade IIb Infected Patients

    by Eugene Bangwen, Nicole Berens‐Riha, Nicky de Vrij, Ann Ceulemans, Isabel Brosius, Elise De Vos, Thao‐Thy Pham, Emmanuel Bottieau, Johan van Griensven, Palmer Masumbe Netongo, et al.

    Previous studies indicated Clade I monkeypox virus infection to be associated with marked elevation of proinflammatory cytokines. This remains unexplored for Clade II‐associated disease, which has different clinical manifestations and prognosis. We used a 65‐plex cytokine, chemokine, and growth factor (CCG) panel to analyze serum samples of 100 male acute Clade IIb mpox patients and 26 healthy controls in Belgium. Cluster analyses revealed no strong or distinct CCG profiles distinguishing mpox patients from controls but suggested trends in certain cytokine modulation. Individual CCG analyses found elevated levels of cytokines (MIF, CD30, IL2R, IL18, APRIL, and TNFRII), chemokines (CCL4, CCL8, CCL22, CCL24, CXCL9, CXCL10, CXCL11, CXCL12, and CXCL13), and growth factors (HGF and VEGFA) in patients, while CCL11 and CXCL5 were significantly suppressed. We detected no differences in key proinflammatory cytokines, IL‐1α, IL‐1β, IL‐6, IL‐8 or anti‐inflammatory cytokines, IL‐4, IL‐10, IL‐13. In patients living with HIV, comparison with pre‐outbreak samples showed an increase in CXCL13 and a decrease in CXCL5, CCL2, CCL24, HGF, SCF, and TWEAK. The absence of discriminatory CCG profiles in Clade IIb mpox patients compared to healthy controls suggests there may be limited clinical applications of those markers.


  • Open Access

    Multi-drug tolerance in Leishmania persister-like cells

    by Allison M Aroni-Soto, Pieter Monsieurs, Odin Goovaerts, Kaoutar Choukri, Basudha Khanal, Wim Adriaensen, Jean-Claude Dujardin, Michael P. Barrett, Malgorzata A. Domagalska

    Leishmaniasis is caused by parasitic protozoa of the genus Leishmania and is found widely across the tropics and sub-tropics, afflicting hundreds of thousands of people. The disease is notoriously difficult to treat. Here, we present evidence of the existence of persister-like cells in cultured Leishmania populations, induced upon exposure to normally lethal doses of antimony, a widely used anti-leishmanial. Persisters are a small fraction of non-proliferative cells with reduced metabolism that are adapted to withstand a variety of environmental assaults, including lethal doses of antimicrobials. We show that Leishmania persister-like cells survive lethal doses of antimonials by adopting a quiescence phenotype characterised by reduced proliferation, constrained metabolism, and diminished mitochondrial membrane potential. What is more, these cells demonstrate cross-tolerance to other anti-leishmanial drugs. Wild-type persister-like cells reverted to similar levels of drug susceptibility once the antimony-induced pressure was removed. Surprisingly, cells which had previously been selected for genetic changes causing resistance to antimony acquired a level of hyper-resistance after transient passage through the quiescent state, without further genetic change. Our results demonstrate the extreme versatility of this eukaryotic pathogen in adaptation to drug pressure and highlight the need for the development of new anti-leishmanials targeting non-proliferative forms.